Purple Biotech receives intention for European patent

Purple Biotech Ltd. filed a 6-K describing a new development for its NT219 drug candidate.

Rhea-AI Filing Summary

Purple Biotech Ltd. filed a 6-K describing a new development for its NT219 drug candidate. The company received an intention to grant a European patent covering combinations of NT219 with immunotherapies or MEK inhibitors, aimed at overcoming tumor resistance. This update was communicated in a press release attached to the filing as Exhibit 99.1.

Insights

Biotech IP and pipeline analyst

Purple Biotech reports an intention to grant a European patent for NT219 combination therapies, strengthening intellectual property around overcoming tumor resistance.

The filing highlights that Purple Biotech received an intention to grant a European patent covering combinations of its NT219 candidate with immunotherapies or MEK inhibitors. This focuses protection on approaches designed to overcome tumor resistance, a key challenge in oncology treatment.

Such an intention to grant, while not yet a final patent, can support the company’s intellectual property position around NT219-based combination strategies in Europe. Subsequent disclosures may clarify the final grant scope, timing, and how this protection interacts with clinical or commercial plans for NT219.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Purple Biotech (PPBT) disclose in this 6-K filing?

Purple Biotech reported receiving an intention to grant a European patent. The patent would cover NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistance, and this update was detailed in a press release attached as Exhibit 99.1.

What is the subject of Purple Biotechs new European patent for NT219?

The patent covers NT219 combination therapies. Specifically, it relates to combinations of NT219 with immunotherapies or MEK inhibitors that aim to overcome tumor resistance, potentially strengthening Purple Biotechs intellectual property around this oncology approach.

How was the NT219 patent news communicated by Purple Biotech (PPBT)?

The company issued a dedicated press release. Purple Biotech announced the intention to grant a European patent for NT219 combinations in a press release titled about receiving such intention, which is attached to the 6-K as Exhibit 99.1.

Does the filing state that the European patent for NT219 is already granted?

The filing refers to an intention to grant, not a final grant. Purple Biotech notes it received an intention to grant a European patent, indicating a positive step in the process, with final grant details not described in this excerpt.

Which combinations are covered by Purple Biotechs intended European patent?

The intended patent covers NT219 with immunotherapies or MEK inhibitors. These combinations are described as designed to overcome tumor resistance, suggesting protection for specific multi-drug treatment strategies involving NT219.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 08:03 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒        Form 40-F ☐

Purple Biotech

On September 10, 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release “Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

September 10, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2